- Home
- TOUR vs CNTX Comparison
TOUR vs CNTX Comparison
Compare TOUR & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOUR | CNTX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.2M | 47.7M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TOUR | CNTX |
|---|---|---|
| Price | $4.99 | $0.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.03 |
| AVG Volume (30 Days) | 4.4K | ★ 1.0M |
| Earning Date | 08-25-2026 | 11-04-2026 |
| Dividend Yield | ★ 24.13% | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.00 | N/A |
| Revenue Next Year | $3.00 | N/A |
| P/E Ratio | $87.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.31 |
| 52 Week High | $7.79 | $3.62 |
Technical Indicators
Market Signals| Indicator | TOUR | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 32.52 |
| Support Level | $4.93 | N/A |
| Resistance Level | $5.31 | $0.40 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 0.00 | 19.71 |
Price Performance
Historical ComparisonAbout TOUR Tuniu Corporation
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. The company offers a large selection of packaged tours, including organized tours and self-guided tours, and travel-related services for leisure travellers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.